In a time where tragedies have become more and more common, life insurance companies have adjusted to these new changes. Policies have generally remained the same, but there are some key differences worth discussing.
 

Insurers have known for a long time that the mortality rate of an insured population is much better than in the general population. This difference is critical for insurers, but there hasn’t been enough insurance data to fully understand mortality improvements, so we must rely on population mortality to guide our analysis.
 

Dr. Achim Regenauer, Chief Medical Officer, presents a high-level overview of targeted cancer therapy – a catch-all term for a spectrum of innovative new cancer therapies that are improving the outlook for patients and moving us closer to precision medicine – and its impact on Life & Health insurers.